Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain tumors and host immune cells, and its expression can be induced or maintained by many factors. The expression of PD-L1 on t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Fei, Zheng, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930423/
https://www.ncbi.nlm.nih.gov/pubmed/29744030
http://dx.doi.org/10.1186/s13578-018-0232-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930423/
https://www.ncbi.nlm.nih.gov/pubmed/29744030
http://dx.doi.org/10.1186/s13578-018-0232-4

Ejemplares similares